Hi Boris,
Until Yahoo takes some real action against violators of their policy, it will not significantly change, they'll be back. Several of us have tried to get more action from their, and their new policy is a small step in the right direction, but as long as they let posters have an infinite numbers of id's easily, it won't change.
In the mean time, while I know you're not into overexuberance about IMGN, I believe were just at the beginning of another big movement up. With November we'll see the first clinical data on C242-DM1, an offering that will give the company sufficient money to bring new drugs to market without having to partner, and the Annual Meeting.
Someone recently indicated how several stocks that had recent similar offerings have done exceptionally well when the offerings were completed. I believe IMGN will do comparably well, perhaps even better. I think much of the newly issued shares will go to Institutions who were waiting for clinical results before becoming involved. I furthermore believe on November 15th, when they must report, we'll find Institutional involvement in the past quarter has increased substantially. By February 15th, the next reporting date, it will have grown far more then the additional 4.6 million share IMHO.
With the additional Institutional ownership we'll be seeing far more Analyst's covering the stock, which will build the demand by retail investors as well. To my way of thinking this can only result in continued substantial price appreciation.
Gary |
